Barringer's Sabre 2000 Successfully Completes U.S. Army's Test Program for Chemical Warfare Agent Detection.

Business Editors

WARREN, N.J.--(BUSINESS WIRE)--Sept. 12, 2000

Barringer Technologies Inc. (Nasdaq: BARR), announced today that its Sabre 2000(R) hand-held detector has successfully completed the U.S. Army's Domestic Preparedness Test Program for Chemical Warfare Agent detection. The test program was established to evaluate the capability of detector platforms to reliably detect the presence of several types of chemical warfare agents. Performance data will be made available to federal, state and local agencies having responsibility for establishing the country's civil defense and first responder capability for a domestic chemical warfare terrorist attack.

Kenneth S. Wood, President of Barringer Technologies commented, "We are very pleased with the results achieved at the Army's test program at Edgewood Arsenal. Our detection capabilities are superior to published results for other detectors. This includes the ability to detect minute amounts of a chemical warfare agent as well as the Sabre's performance in the presence of potential interfering substances that could be encountered in the surrounding environment. The significance of these results is that we now have independent laboratory and field tests verifying our chemical warfare detection capabilities, which will facilitate our penetration into the various chemical warfare market areas."

Mr. Wood continued, "We have begun to demonstrate our capabilities to the many government agencies charged with the responsibility of protecting the general population from these terrorist threats.

We believe the requirement for detection equipment to meet this threat will significantly enlarge the markets we presently serve. Feedback that we have received from potential customers about our capabilities is very positive, and we have already received initial orders for Sabre 2000(R) chemical warfare detectors."

Headquartered in Warren, New Jersey, Barringer Technologies Inc. is principally engaged in developing, manufacturing, and marketing of high technology products for drug, explosive and chemical detection and other security and industrial applications. The Sabre 2000(R) and the IONSCAN(R) are the Company's proprietary trace particle drug and explosive detection units.

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended that are based on the beliefs of the Company's management as well as assumptions made by and information currently available to the Company's management. When used in this press release, the words "estimate," "project," "believe," "anticipate," "intend," "expect," "plan," "predict," "may," "should," "will," the negative thereof and similar expressions are intended to identify forward-looking statements. Such statements reflect the current views of the Company with respect to future events based on currently available information and are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements. Factors that could cause actual results to differ materially from the Company's expectations include, but are not limited to, the following: general economic and political conditions, conditions in the markets for the Company's products, and risks associated with new product introductions such as: manufacturing delays, unexpected manufacturing costs, increased selling costs, failure to properly estimate demand, delays in market acceptance, increased warranty expenses, delays in the development of new applications, risks related to the Company's ability to successfully commercialize new applications and the timing thereof. Other factors may be described from time to time in the Company's public filings with the Securities and Exchange Commission, news releases and other communications. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to release publicly any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.